Autonomix Medical CEO Brad Hauser to Present at H.C. Wainwright Conference
PorAinvest
martes, 2 de septiembre de 2025, 8:33 am ET1 min de lectura
AMIX--
In addition to the presentation, management will be available for one-on-one meetings with qualified investors who are registered to attend the conference. The presentation will be available via video webcast starting on September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website [1].
Autonomix's first-in-class platform system technology includes a catheter-based microchip sensing array that has the potential to detect and differentiate neural signals with greater sensitivity than currently available technologies. This technology aims to enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. The company is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions [2].
For more information about the conference, visit the conference website. For further details on Autonomix Medical, Inc., please visit their website at autonomix.com and connect with them on X, LinkedIn, Instagram, and Facebook.
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142674/0/en/Autonomix-Medical-Inc-to-Present-at-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.stocktitan.net/news/AMIX/autonomix-medical-inc-to-present-at-h-c-wainwright-27th-annual-udnhxuotrunk.html
Autonomix Medical, a medical device company, announced that CEO Brad Hauser will present at the H.C. Wainwright 27th Annual Global Investment Conference. Management will also be available for one-on-one meetings with registered investors. The presentation will be webcast on-demand starting on September 8, 2025.
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, has announced that its CEO, Brad Hauser, will present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held September 8-10, 2025, in New York, NY.In addition to the presentation, management will be available for one-on-one meetings with qualified investors who are registered to attend the conference. The presentation will be available via video webcast starting on September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website [1].
Autonomix's first-in-class platform system technology includes a catheter-based microchip sensing array that has the potential to detect and differentiate neural signals with greater sensitivity than currently available technologies. This technology aims to enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. The company is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions [2].
For more information about the conference, visit the conference website. For further details on Autonomix Medical, Inc., please visit their website at autonomix.com and connect with them on X, LinkedIn, Instagram, and Facebook.
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142674/0/en/Autonomix-Medical-Inc-to-Present-at-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.stocktitan.net/news/AMIX/autonomix-medical-inc-to-present-at-h-c-wainwright-27th-annual-udnhxuotrunk.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios